AMGN Down 10% in 3 Months: How to Play the Stock as Tariff Woes Linger
Amgen's AMGN stock has declined 10.4% in the past three months. A lot of this price decline is related to the broader macroeconomic uncertainty.
Stocks have been on a roller-coaster ride since President Trump unveiled sky-high tariffs in early April and China came up with retaliatory tariffs. Last week, China and the United States struck a deal that eased trade tensions and resulted in a stock market recovery. Though the massive tariffs imposed by the United States and retaliatory tariffs by China and some other countries are now on a pause, it is only a temporary suspension, and no one knows what will happen after the 90-day tariff suspension ends. The uncertainty around tariffs and trade production measures remains, which has muted economic growth.
Although pharmaceuticals have been exempted from tariffs in the first round, they could be Trump's target in the next round, considering the President's goal to shift pharmaceutical production back to the United States, primarily from European and Asian countries.
Trump and the Republican government also continue to stress on the control of drug prices with the latest attempt being his 'most favored nations' policy.'
Let's understand AMGN's strengths and weaknesses to better analyze how to play the stock in the uncertain macro environment.
Amgen's revenues grew 9% year over year in the first quarter of 2025, driven by growing patient demand for its innovative medicines.
Amgen is seeing declining revenues from oncology biosimilars and some legacy established products like Enbrel. Pricing headwinds and competitive pressure are hurting sales of many products. Sales of some key brands, like Otezla and Lumakras, have been lukewarm. However, revenues from key older medicines like Prolia, Repatha and Blincyto and new drugs like Tavneos and Tezspire are driving the top line. Rare disease drugs like Tepezza, Krystexxa and Uplizna, added from last year's acquisition of Horizon Therapeutics, are also boosting top-line growth.
Amgen is also evaluating Kyprolis, Otezla, Nplate, Repatha, Lumakras, Tezspire, Uplizna and Blincyto for additional indications. Approval for the expanded use of these drugs can potentially drive further top-line growth. Uplizna was approved for IgG4-related disease in the United States in April 2025.
Amgen's regulatory application for Uplizna in myasthenia gravis is under review in the United States, with an FDA decision expected on Dec. 14, 2025. Tezspire is under review in the United States for chronic rhinosinusitis with nasal polyps, with an FDA decision expected on Oct. 19, 2025.
Amgen has invested several billion dollars in M&A deals over the last decade, which has bolstered its product portfolio and diversified its pipeline.
Amgen is developing MariTide, a GIPR/GLP-1 receptor, as a single dose in a convenient autoinjector device with a monthly and, possibly, less frequent dosing. This key feature differentiates it from Eli Lilly's LLY and Novo Nordisk's NVO popular GLP-1-based obesity drugs, Zepbound and Wegovy, which are weekly injections.
In clinical studies, it has shown predictable and sustained weight loss and a meaningful impact on cardiometabolic parameters.
In March, Amgen initiated two phase III studies on MariTide in obesity as part of its comprehensive MARITIME phase III program. Separate phase III studies on MariTide in obesity, with or without type II diabetes, are currently enrolling patients. Additional MARITIME phase III studies on MariTide in specific obesity-related conditions are expected to be launched throughout 2025. Separate phase II studies on obesity and type II diabetes are also ongoing, with data readouts expected in the second half.
An interesting BiTE drug, Imdelltra (tarlatamab), was approved for pre-treated advanced small cell lung cancer (ES-SCLC) in May 2024. Several phase III studies are currently ongoing on tarlatamab in earlier-line settings across extensive-stage and limited-stage SCLC. Imdelltra is believed to have blockbuster potential, as there are limited treatment options in late-line SCLC. Another important candidate, rocatinlimab, is being evaluated in phase III studies for atopic dermatitis and prurigo nodularis.
Several data readouts are expected over the next six to 12 months, which could be important catalysts for the stock.
Amgen has successfully launched some new biosimilar products this year, which generated impressive sales in the first quarter. In January, Amgen launched Wezlana, the first biosimilar version of J&J's JNJ blockbuster drug, Stelara. Wezlana generated sales of $150 million in the quarter. Wezlana was approved by the FDA in 2023 but was not launched until January 2025, as per a settlement with J&J.
Amgen launched the first biosimilar version of Regeneron's Eylea, Pavblu, in the fourth quarter of 2024, which generated sales of $99 million in the first quarter of 2025. Another key biosimilar product, Bekemv, a biosimilar version of AstraZeneca's Soliris, was approved in the United States in May 2024 and was launched in the second quarter of 2025.
In the first quarter of 2025, Amgen's biosimilar products generated impressive sales of $735 million, which rose 35% year over year. Amgen's new biosimilar launches will play a key role in mitigating the impact of Amgen's upcoming loss of exclusivity (LOE) over the next few years.
Phase III studies are ongoing to evaluate biosimilar versions of Bristol-Myers' Opdivo (ABP 206), Merck's Keytruda (ABP 234) and Roche's Ocrevus (ABP 692).
Patents for RANKL antibodies (including sequences) for Prolia and Xgeva expired in February 2025 in the United States and will expire in November 2025 in some European countries. Sales of these best-selling drugs are expected to erode significantly in 2025, mainly in the second half, due to patent erosion.
Sales of Amgen's rare disease drugs, mainly Tepezza, have slowed down, which is a concern.
The Medicare Part D redesign is expected to hurt sales of some of Amgen's drugs in future quarters. Enbrel and Otezla have been selected by the Centers for Medicare & Medicaid Services for Medicare Part D price setting beginning in 2026 and 2027, respectively.
Pricing headwinds and competitive pressure are hurting sales of many products. Weakness in some key brands like Otezla and Lumakras creates potential revenue headwinds.
Amgen's stock has risen 7.3% so far this year against a decrease of 3.1% for the industry. The stock has also outperformed the sector and S&P 500 index, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Amgen is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 13.12 forward earnings, which is lower than 14.74 for the industry. The stock is also trading below its five-year mean of 13.80.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for earnings has risen from $20.59 to $20.79 per share for 2025 over the past 30 days. For 2026, the consensus mark for earnings has risen from $21.19 to $21.23 per share over the same timeframe.
Image Source: Zacks Investment Research
After analyzing the factors discussed above, we believe the company is well placed to maintain long-term revenue growth, driven by continued strong volume growth of key drugs, Repatha, Evenity and Prolia and increasing contribution from new innovative medicines like Tezspire, Tavneos and Imdelltra. It is expected to see continued clinical success from its mid- to late-stage pipeline. Though the initial data from MariTide studies were below expectations, MariTide has the potential to be a game-changer for Amgen.
Along with all these factors, Amgen's consistently rising estimates, reasonable valuation and decent stock price appreciation are good enough reasons for those who own this Zacks Rank #3 (Hold) stock to stay invested for now. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
Amgen Inc. (AMGN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
5 minutes ago
- CNN
Trump lays into Musk, suggesting he has ‘Trump derangement syndrome'
President Donald Trump appeared to confirm the deterioration of his relationship with Elon Musk, saying he was 'very disappointed' in the tech billionaire after Musk repeatedly blasted the president's sweeping domestic agenda bill in recent days. 'Elon and I had a great relationship. I don't know if we will anymore,' Trump told reporters in the Oval Office less than one week after the two exchanged effusive praise on Musk's last day as a special government employee. Since then, Musk has strongly criticized what Trump calls his 'Big, Beautiful Bill' that has passed the House and faces an uncertain path forward in the Senate. On Tuesday, Musk called the bill a 'disgusting abomination.' Trump and Musk have not spoken since Musk lashed out at the legislation, a source familiar with the dynamic told CNN. 'He knew every aspect of this bill. He knew it better than almost anybody, and he never had a problem until right after he left,' Trump said, adding that while Musk has not yet personally attacked him, the president expected that could be next. Trump repeatedly claimed that Musk's concerns with the bill were centered on the repeal of electric vehicle subsidies that benefitted Tesla. Musk has admitted his company has struggled in the wake of his political involvement. Musk didn't wait to respond, posting his reactions in real time on his social media platform X. 'Without me, Trump would have lost the election, Dems would control the House and the Republicans would be 51-49 in the Senate,' Musk said. He added: 'Such ingratitude.' Musk denied Trump's claim that the Tesla CEO knew the inner workings of the bill ahead of time, and countered that the elimination of EV tax incentives has nothing to do with his opposition to the massive domestic policy bill. 'Whatever. Keep the EV/solar incentive cuts in the bill, even though no oil & gas subsidies are touched (very unfair!!), but ditch the MOUNTAIN of DISGUSTING PORK in the bill' Musk in a separate post. 'In the entire history of civilization, there has never been legislation that both big and beautiful. Everyone knows this! Either you get a big and ugly bill or a slim and beautiful bill. Slim and beautiful is the way.' One Republican strategist who has worked closely with the tech billionaire downplayed the idea that Musk's opposition is only about the EV subsidies, telling CNN that Musk was genuinely troubled by projections of how much the bill would add to the deficit – the reasoning Musk has publicly cited on multiple occasions. The nonpartisan Congressional Budget Office has estimated that the legislation passed by the House would increase the deficit by $2.4 trillion. During Thursday's Oval Office appearance alongside German Chancellor Friedrich Merz, Trump reminisced about his campaign bromance with Musk, who contributed at least a quarter-billion dollars to efforts supporting Trump's 2024 presidential bid and once called himself Trump's 'first buddy.' 'Elon endorsed me very strongly. He actually went up and campaigned for me. I think I would have won – Susie would say I would have won Pennsylvania easily anyway,' Trump said, referring to his chief of staff Susie Wiles, appearing to hint at tensions between Wiles and Musk. Trump appeared to moderate his tone at times, saying he 'always liked Elon' – before implicitly accusing him of so-called 'Trump Derangement Syndrome.' 'He's not the first – people leave my administration, and they love us, and then at some point they miss it so badly, and some of them embrace it, and some of them actually become hostile. I don't know what it is. It's sort of 'Trump derangement syndrome,' I guess they call it, but we have it with others too,' he said. 'They leave, and they wake up in the morning, and the glamour is gone,' he continued. 'The whole world is different, and they become hostile. I don't know what it is.' Kristen Holmes contributed to this report.
New York Post
6 minutes ago
- New York Post
Hedge fund titan Ken Griffin rips White House over tax bill
Hedge fund titan Ken Griffin ramped up his war of words with the Trump White House on Wednesday, blasting the president's so-called 'Big, Beautiful' tax bill for adding to Uncle Sam's eye-popping $36 trillion debt pile. The 56-year-old CEO of Citadel, who is worth $42 billion according to Forbes, told the business magazine's annual Iconoclast summit in New York City that if the bill passed, the country would 'unquestionably add several trillion dollars' to the US debt. 'There are a lot of question marks as to why we are continuing to restart tax cuts when we have a fiscal deficit that is this big,' Griffin said at the business magazine's annual Iconoclast summit in lower Manhattan Advertisement 4 Griffin warned that the Trump tax bill will only add to America's debt pile. REUTERS 'The United States' fiscal house is not in order,' Griffin added. 'You cannot run deficits of 6 or 7% at full employment after years of growth. That is just fiscally irresponsible.' Analysis by the nonpartisan Congressional Budget Office forecasts that there is a $2.4 trillion black hole in the president's flagship tax bill. Griffin, who moved his firm from Chicago to Miami in 2022, likewise warned that the administration should rein in spending and that investors are already worried about America's finances — posing major risks in the bond markets. Advertisement 'US default prices are probably the same as Italy or Greece,' he said, referring to the so-called credit default swap markets where investors can bet on whether someone will fail to pay their bills. The GOP megadonor also took aim at Trump for criticizing Walmart CEO Doug McMillon after he warned of needing to raise prices in response to higher import costs. 'We should not criticize CEOs for being honest, right? And that's all the CEO of Walmart was doing,' he told the audience in lower Manhattan. 'Shame on the administration.' Advertisement The Post has approached the White House for comment. 4 Elon Musk, who has only recently left the Trump administration, has been repeatedly griping about the bill on his social media platform X, formerly known as Twitter. REUTERS More broadly, Griffin lamented the 'uncertainty' that now clouds investment decisions in the US as a result of policies that have 'called into question American exceptionalism.' 'The administration's attempts to use tariffs come at a dear price for the US economy and come at a dear price for the US consumers, who will undoubtedly pay higher prices,' Griffin told the audience at the upmarket Cipriani ballroom on Broadway in lower Manhattan. Advertisement 'Why do we aspire to bring back to the United States jobs that are actually moving out of China into lower-cost jurisdictions? Why are we aspiring to be the nation of the lowest cost and the lowest-paid workforce in the world? That makes no sense to me.' 4 The tariff tiff blew up at the Beverly Hills Hilton where Trump's allies organized a rival VIP welcome party to go up against Griffin's traditional Milken opener. Bloomberg via Getty Images Griffin, who voted for Trump in November's presidential election, has been a staunch critic of his administration's tariff and trade policies since the real estate mogul's second inauguration earlier this year. The row between the two men spilled over at the Milken Institute Global Conference in Beverly Hills last month, where allies of President Trump organized a rival VIP welcome bash to go up against the Citadel supremo's traditional opening reception. Trump unveiled his tariff plans on April 2, which he dubbed Liberation Day, as he sought to renegotiate new trade deals with countries he believed were treating the United States unfairly. 4 Griffin used a Forbes summit to launch a string of broadsides at the Trump administration over its trade and tariff policies. AP The move has since faced a string of legal challenges, with negotiations failing to bear any fruit until now, apart from an agreement with post-Brexit Britain that was announced on May 8. But discussions with the European Union, one of America's largest trading partners, have faltered, as The Post exclusively reported on May 7.
New York Times
6 minutes ago
- New York Times
Trump Administration Live Updates: President and Musk Spar Over Policy Bill as Their Relationship Frays
As Germany's chancellor, Friedrich Merz, sat beside him watching in silence, President Trump compared Russia and Ukraine to two fighting children who needed to work out their differences for a while before anyone could intervene. 'Sometimes you see two young children fighting like crazy,' Mr. Trump said on Thursday in an Oval Office news conference. 'They hate each other, and they're fighting in a park, and you try and pull them apart. They don't want to be pulled. Sometimes you're better off letting them fight for a while and then pulling them apart.' 'And I gave that analogy to Putin yesterday,' Mr. Trump added. 'I said, 'President, maybe you have to keep fighting and suffering a lot, because both sides are suffering, before you pull them apart, before they're able to be pulled apart.'' Mr. Merz, who became Germany's chancellor last month, had come to Washington hoping to persuade Mr. Trump to play a more active role in defending Ukraine by bringing unrivaled U.S. power to the task of forcing Russia to end its invasion of its smaller neighbor. But he got a very different response. Mr. Trump essentially threw up his hands, saying that there was nothing the United States could do right now to bring the Russia-Ukraine war to an end. Mr. Trump repeatedly promised during the presidential campaign that he could make peace between the warring nations within 24 hours, but he now says he was being sarcastic. Four months into his second term, Mr. Trump is talking about the war as if he is a bystander. When a reporter asked him at Thursday's news conference whether he was going to put more sanctions on Russia, as he had previously threatened, Mr. Trump equivocated. He suggested he would know when the moment had arrived to pile on more pressure, but that it hadn't yet. He also suggested that Ukraine might come in for punishment. 'We'll be very, very, very tough, and it could be on both countries to be honest,' Mr. Trump said. 'You know, it takes two to tango.' The exchange was notable because Mr. Trump has said very little about the Russia-Ukraine war in recent weeks and almost nothing about Ukraine's stunning drone attack over the weekend against nuclear-capable bombers inside Russia. After calling Mr. Putin 'absolutely crazy' last month, Mr. Trump shifted his tone and said he wanted to give the Russian leader 'two weeks' to show signs of progress. He then dropped the timeline altogether in his statement on social media on Wednesday, instead simply relaying Mr. Putin's intent to retaliate against Ukraine as if he was a commentator without a stake in the outcome. Mr. Trump continued in that vein on Thursday, despite a plea from Mr. Merz to use American power to force Russia's retreat. Mr. Merz reminded the president that the anniversary of the D-Day operation was Friday, June 6, 'when the Americans once ended a war in Europe.' 'And I think this is in your hand, in specific, in ours,' Mr. Merz added. Mr. Trump interjected with a joke about the Nazis. 'That was not a pleasant day for you,' he said, referring to America's defeat of Adolf Hitler. Mr. Merz countered that, 'in the long run, Mr. President, this was the liberation of my country from Nazi dictatorship.' 'We know what we owe you,' he added, 'but this is the reason why I'm saying that America is, again, in a very strong position to do something on this war and ending this war.' Mr. Trump made no commitments. Instead, he boasted about the U.S. economy and military recruitment numbers under his leadership. And then he compared the war to children fighting, or a hockey game. 'They fight, fight, fight,' he said. 'Sometimes you let them fight for a little while. You see it in hockey. You see it in sports. The referees let them go for a couple of seconds. Let them go for a little while before you pull them apart.' Mr. Trump said he told Mr. Putin: 'Don't do it. You shouldn't do it. You should stop it.' But he did not seem confident that his words had any effect. In the president's telling, Mr. Putin replied that he had no choice but to attack based on Ukraine's strikes over the weekend, and, Mr. Trump added, 'it's probably not going to be pretty.' Zolan Kanno-Youngs contributed reporting.
